Radius Pharmaceuticals Appoints Renata Sklodowska, M.D. as SVP of Medical Operations

BOSTON, MA, June 25, 2024 – Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc., has announced the appointment of Renata Sklodowska, M.D. as Senior Vice President of Medical Operations. Dr. Sklodowska brings over fifteen years of experience in clinical development, regulatory, and medical affairs, and will report directly to Scott Briggs, the Chief Executive Officer. Her responsibilities will encompass oversight of Medical Operations, including Medical Affairs, Regulatory Affairs, and Pharmacovigilance (PV).

Scott Briggs expressed his enthusiasm for Dr. Sklodowska joining the team, highlighting her extensive experience in the pharmaceutical industry and her proven leadership in global medical and scientific affairs. He emphasized the importance of her patient-centric approach and her ability to form alliances with medical, scientific, and patient communities, which will be crucial for the company's ongoing efforts with their key products, TYMLOS® and BINOSTO®.

Dr. Sklodowska has a robust background in international pharmaceutical and biotech sectors, with expertise in Medical and Scientific Affairs as well as commercial operations. Her career spans over fifteen years, primarily in the rare diseases domain including Endocrinology, where she has successfully prepared and supported multiple product launches and managed product portfolios. She has demonstrated capabilities in leading Medical Affairs activities for both development stage and marketed drugs and has a track record of building and leading cross-functional teams to achieve business goals. Additionally, she has established global PV systems and overseen drug safety and risk management activities for numerous marketed products.

Dr. Sklodowska stated her excitement about joining Radius and contributing to the company’s growth by leveraging her experience. She aims to support TYMLOS® and BINOSTO® while providing strategic medical insights to explore potential opportunities for expanding Radius's portfolio.

Prior to her new role at Radius, Dr. Sklodowska held leadership positions in clinical development and medical affairs at several biotech and global pharmaceutical companies. Most recently, she served as Vice President of Medical Affairs at F2G and Recordati Rare Diseases. She earned her Doctor of Medicine degree from the Medical University of Bialystok, Poland, where she also practiced as an attending physician.

Radius Pharmaceuticals, a global biopharmaceutical company, is dedicated to addressing unmet medical needs in bone health and related fields. Their leading product, TYMLOS® (abaloparatide) injection, gained the U.S. FDA approval in April 2017 for treating postmenopausal women with osteoporosis at high risk for fracture, and in December 2022 for increasing bone density in men with osteoporosis at high risk for fracture. Recently, Radius also secured an exclusive licensing and distribution agreement for the U.S. rights to BINOSTO® (alendronate sodium) effervescent tablet for oral solution, further solidifying the company’s footprint in bone health.